June 4, 2025

Drs. Fang and Liu were awarded a Lurie Cancer Center Research Innovation Challenge Award to advance USP22 inhibitor development toward clinical trial readiness.

May 10, 2025

Dr. Deyu Fang moderated a leading tumor immunology session at the 2025 AAI Annual Meeting, showcasing ExoMira’s continued impact in the cancer immunotherapy space.

May 7, 2025

Dr. Huiping Liu gave an invited talk on CTC cluster plasticity and immune evasion at the 2025 FASEB Cancer Conference in Hong Kong, reinforcing ExoMira’s scientific leadership.

March 20, 2025

ExoMira receives an outstanding fundable score on a highly competitive SBIR grant, positioning the company for future scale-up toward clinical trials.

March 10, 2025

ExoMira appoints Yan He as Director of Business & Clinical Development, strengthening its business development, clinical, and regulatory leadership as ExoMira advances toward first-in-human studies.

January 15, 2025

ExoMira appoints Dr. Alex Le as Executive Advisor and Board Member, bolstering the company’s strategic growth, commercialization planning, and industry connectivity as it scales its pancancer immunotherapy platform.